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Abstract 
Background: In silico target prediction of compounds plays an important role in drug discovery. The chemical 
similarity ensemble approach (SEA) is a promising method, which has been successfully applied in many drug-related 
studies. There are various models available analogous to SEA, because this approach is based on different types of 
molecular fingerprints. To investigate the influence of training data selection and the complementarity of different 
models, several SEA models were constructed and tested.
Results: When we used a test set of 37,138 positive and 42,928 negative ligand-target interactions, among the five 
tested molecular fingerprint methods, at significance level 0.05, Topological-based model yielded the best precision 
rate (83.7 %) and F0.25-Measure (0.784) while Atom pair-based model yielded the best F0.5-Measure (0.694). By employ-
ing an election system to combine the five models, a flexible prediction scheme was achieved with precision range 
from 71 to 90.6 %, F0.5-Measure range from 0.663 to 0.684 and F0.25-Measure range from 0.696 to 0.817.
Conclusions: The overall effectiveness of all of the five models could be ranked in decreasing order as follows: Atom 
pair ≈ Topological > Morgan > MACCS > Pharmacophore. Combining multiple SEA models, which takes advantages 
of different models, could be used to improve the success rates of the models. Another possibility of improving the 
model could be using target-specific classes or more active compounds.
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Background
In recent years, with the increasing cost of drug devel-
opment and the inconsistent and slow speed of drug 
approval, predicting new targets for approved drugs has 
become a popular research area [1–8]. It is well known 
that drugs interact with multiple targets rather than 
with a single target (called the off-target effect), and this 
fact can be beneficial [9] or harmful [10] (known as side 
effects or toxicity). Drug discovery methods that take 
advantage of the polypharmacological nature of drugs 
are becoming more popular [11], because drug discov-
ery starting from approved drugs can benefit from the 
elimination of many toxicological and pharmacokinetic 
assessments.
With the ever-increasing public availability of bioac-
tivity data [12], it is possible to construct reliable target-
prediction models using statistical or machine learning 
methods. Paolini et  al.  [13] identified different types of 
targets within the human pharmacological interaction 
network using Bayesian classification models. Using 
activity data from the ChEMBL17 database, Afzal et  al.   
[1] evaluated a multi-label multi-class classification 
model and a single-label multi-class classification model. 
In 2007, Keiser et  al.  [5] developed the chemical simi-
larity ensemble approach (SEA), which relates proteins 
to one another based on the chemical similarity among 
their bound ligands. Since then, the SEA and SEA-like 
methods have been successfully applied in new target 
identification for old drugs [3, 5, 8]/natural products [14], 
for side-effect prediction [15] and for the prediction of 
potential anatomical therapeutic indications (ATCs) of 
approved drugs [16]. Moreover, studies [17] have shown 
that there is a startling difference between ligand-based 
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and sequence-based approaches, and in most case the 
ligand-based similarity approach is more informative 
for pharmacology than the sequence-based approach 
[4]. Therefore, relating proteins on the basis of the 
chemical similarity of their ligands, which is motivated 
by the BLAST theory [18], rather than by their protein 
sequences, could provide new insights into the relation-
ships between structurally dissimilar but functional 
related proteins.
An SEA model can be built based on different types of 
molecular fingerprints. Hert et al.  [4] evaluated the per-
formance of several commonly used fingerprints in SEA, 
and their results showed that ECFP_4 (extended connec-
tivity fingerprint with radius equals 4) yielded the best 
performance, but the others were comparable. Hence, the 
chemical similarity criteria of small molecules play key 
roles in SEA modeling. In this study, to investigate the 
influence of different fingerprints, training data sets, and 
activity thresholds on SEA models, we constructed five 
SEA models based on five fingerprints—Morgan, Atom 
pair, Topological, MACCS (molecular access system) 
keys and Pharmacophore—and also a multi-voting SEA 
model based on the 5 different fingerprint-based SEA 




The ChEMBL database is a good open access data source 
for drug discovery [12]. In this study, the activity data 
from ChEMBL19 were used for the training set, whereas 
the newly reported activity data in ChEMBL20, compared 
to ChEMBL19, were used as the test set. The following 
steps were performed to create the training sets. First, 
as shown in Fig. 1, molecules were curated by removing 
salt and fragments and by filtering out molecules with 
MWs (molecule weights) larger than 1000. Second, for 
target-ligand pairs with multiple activity values, the geo-
metric mean was used. Only targets labeled with SIN-
GLE PROTEIN were used, and targets with fewer than 5 
ligands were also excluded; Third, three different activity 
thresholds (pChEMBL values 5, 6, and 7—the pChEMBL 
value is a ChEMBL-converted value, which is a negative 
logarithm of the published activity [19], so 10 μm equals 
a pChEMBL value of 5) were applied to generate three 
datasets. Fourth, considering computational efficiency 
and data balance, although SEA has a robust set size [5], 
3000 diverse ligands were picked for targets with ligand 
set size exceeding 3000. To prepare the test set, the same 
procedure was applied but with the difference that only 
one activity threshold (pChEMBL ≥ 5) was used. In addi-
tion, to test the SEA on a specific protein family, a kinase-
specific training set and a test set were created using the 
same strategy from the kinase activity data of ChEMBL19 
and ChEMBL20. Finally, six data sets—training sets with 
activity thresholds 10, 1 and 0.1 µm, a test set, a kinase 
training set and a kinase test set—were generated  (see 
Additional files 1, 2, 3, 4, 5, 6). The data statistics are 
shown in Table 1.  
Similarity evaluation and performance validation 
measures
Only 2D structural similarities were considered in this 
study. Six different molecular representations were cal-
culated including Morgan (RDKit [20] implementation, 
similar to the ECFP/FCFP fingerprint [21]), Atom pair fin-
gerprints [22], Topological torsions fingerprints, MACCS 
keys fingerprints, 2D pharmacophore fingerprints and 
SHED descriptors [23]. The first five fingerprints are binary 
vectors that encode the presence or absence of a predefined 
Fig. 1 Workflow of SEA. Data workflow and simple procedure of 
building an SEA model
Table 1 Statistics of the training and test sets
The size of 4 training data sets and 2 test sets. Numbers in brackets denote 
activity thresholds
Data set Target Molecule Ligand-target 
pair
Active
Training set (5) 2,809 393,090 666,313 All
Training set (6) 2,297 294,877 407,296 All
Training set (7) 1,711 179,710 246,651 All
Kinase training set (5) 429 42,164 101,502 All
Test set 1190 26,498 80,066 37,138
Kinase test 259 2,225 3010 2,192
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feature (e.g., a fragment), and the SHED descriptors were 
calculated based on the information-theoretical concept 
of Shannon entropy to quantify the variability in a feature-
pair distribution [23]. A SHED descriptor is a 10-dimen-
sional array, in which each variable ranges from 0 to 20. The 
average similarities of the 5 binary fingerprints and SHED 
descriptors on the active molecules of 2089 ligand sets (of 
different targets) from the training set were summarized in 
the (see Additional file 7: Fig. S1).
For binary fingerprint similarity measurements, the Tan-
imoto coefficient (TC) was used, which is given by Eq.  1:
where S represents the coefficient, a and b are the on bits 
of A and B, and c is common to both bits. Moreover for 
SHED descriptors, the similarity of A and B is given by 
Eq. 2:
where DIST(A, B) denotes the Euclidean distance between 
A and B.
The performances of each model were evaluated with 
respect to accuracy, precision, sensitivity, specificity and 
Fβ-Measure as shown in the Eqs. (3–7). The Fβ-Measure 
is the harmonic mean of precision and sensitivity. It com-
bines precision and sensitivity in a single metric. More 
specifically, the Fβ-Measure is a weighted harmonic 
mean of precision and sensitivity in which β measures 
the effectiveness of retrieval with respect to a user who 
attaches β times as much importance to sensitivity as pre-
cision. For example, the F0.5-Measure and F0.25-Measure 
weights precision two and four times more than sensi-
tivity, respectively. In this study, due to the incomplete 
experimental evidence of the relationship of all ligand-
target pairs in both test and training data set, the multi-
label classification problem, that a ligand may be active 
against more than one target, was convert to binary 
classification. Thus, the false positive rate obtained is 
underrated, which will be discussed in the result section. 
Under this circumstances, precision is more important 
than sensitivity, therefore, two variations of Fβ-Measure, 
F0.5-Measure and F0.25-Measure together with precision, 


















where TP, FP, TN and FN denote true positive, false posi-
tive, true negative and false negative respectively.
SEA model implementation
The procedures for building SEA models were derived 
from a reference [5], with minor changes. Here, a brief 
summary is provided. The chemical similarity of two sets 
of ligands can be accessed by the sum of the chemical 
similarities between each pair of ligands. However, this 
process will render the value very sensitive to the size of 
the data, to noise and to false positive data. To minimize 
the influence of noise, the original SEA [5] method intro-
duced the Raw Score (RS) (Eqs. 8, 9), which was defined 
as the sum of the ligand-pair TCs over all of the pairs with 
TC ≥ TS (Tanimoto threshold). Then, RS was converted 
to a Z-score and P value (see eqs.10–14), which were 
used to indicate the significance of the RS. In addition, 
TS was determined by the best fitness of EVD (extreme 
value distribution) using the chi-square test, indicating 
that only significant similarities were considered contri-
butions to set-set similarity. This work followed Keiser 
et al.’s [5] procedures to fit TS, with RS calculated for all 
TC thresholds from 0.00 to 0.99 with a step size of 0.01. 
As described in Fig.   1, after data curation, the back-
ground data sets were randomly created with set sizes 
ranging from 10 to 1000 and an interval step of 10, which 
results in 4950 pairs of molecular data set. Then, pairwise 
RS of data sets were calculated, this RS calculation proce-
dures is described in detail using its pseudo code (illus-
trated in Algorithm 1). This procedure was repeated 100 










Fβ-Measure = (1+ β
2)×
Precision× Sensitivity










TC(a, b) if TC(a, b) ≥ TS;
0 if TC(a, b) < TS.
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where s is the product of set A and B, Fmean and Fsd are:
Functions Fmean and Fsd were used to calculate the 
expected raw score mean and standard deviation, and 
the parameters µ, φ and η were determined by fitting 
the random background statistical model (see the Addi-
tional file  7: Fig. S2 and S3). Considering the fact that 
for z ≥ 28 , computing ez exceeds the numerical preci-
sion of most programming languages, therefore a Taylor 
expansion is employed instead [5]. Then, the P value of a 

























Generally, 10 µm has been used as activity cutoff in many 
works [24, 25]. However, to investigate the influence 
of different activity thresholds, three SEA models were 
constructed with activity thresholds of 10, 1 and 0.1 µm , 
respectively. All the three models were built based on 
Morgan fingerprint. The result, as shown in Table  2, 
showed that, at the significance level of P value ≤0.05, the 
model with a threshold of 0.1 µm yielded the best preci-
sion of 95.8  % and specificity of 99.7  %, but a very low 
sensitivity (true positive rate or recall) of 7.2 %; however, 
the model with a threshold of 10 µm yielded the best 
accuracy (67.6  %), sensitivity (38.2  %), and Fβ-Measure 
(F0.5-Measure = 0.57, F0.25-Measure = 0.772). And the 
performance of the model with 1 µm as threshold is in 
between the above two models. This result should not 
come as surprise because a higher activity threshold 
indicates a higher quality of the training set, as well as a 
smaller size of the set. It must be point that, of the 1190 
* 26,489 ligand-target pairs in test set, Morgan model 
with threshold 10 µm gave 65,772 pair of positive pre-
dictions (P value ≤0.05), and most of these predictions 
Algorithm 1 Raw score calculation
1: set a size← 10;
2: set b size← 10;
3: tc threshold← 0;
4: rawscore list← empty list;
5: while set a size is less than or equal to 1000 do
6: while set b size is less than or equal to 1000 do
7: set a← random draw molecules of set a size from background molecule;
8: set b← random draw molecules of set b size from background molecule;
9: sim list← Tanimoto coefficient of each pair of molecule from set a and set b;
10: append set a× set b to rawscore list;
11: while tc threshold ≤ 1.0 do
12: rawscore← 0;
13: for all sim that sim ≥ tc threshold do
14: rawscore← rawscore+ sim;
15: end for
16: append rawscore to the end of rawscore list;
17: tc threshold← tc threshold+ 0.01;
18: end while
19: set b size← ligand set b size+ 10;
20: end while
21: set a size← ligand set a size+ 10;
22: end while
23: return rawscore list;
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haven’t been proved by experiment. Here we took a con-
servative estimate of the real result that the false positive 
rate was underestimated. Therefore, in the following sec-
tions, F0.5-Measure and F0.25-Measure were used as the 
measure. On the other side, at the significance level of 
P-value ≤0.01, the precision, accuracy F0.5-Measure and 
F0.25-Measure of the model with a threshold of 10 µm 
reached at 91.6, 67.9 %, 0.684 and 0.883 respectively but 
with the expense of reduction of sensitivity (33.9  %). 
Thus, in practice, it depends on the researchers to decide 
which model to use, according to the actual situation, 
need broader alternatives of ligand-target interaction 
pair for a few of potential molecule or a higher predic-
tive accuracy rate for high-throughput target identifica-
tion for a large molecule set. For consistency, hereafter 
in this paper, unless otherwise specified, the models were 
built using the training data set, filtered with an activity 
threshold of 10 µm.
Fuzzy representation of compounds
The two-dimensional Pharmacophore fingerprint imple-
mented in the RDKit [20] package was employed to inves-
tigate the influence of the “fuzziness” of the representation 
of compound structures in the SEA model. Details of the 
definition can be found in the RDKit online document 
(http://rdkit.org/docs/RDKit_Book.html). The differ-
ent levels of fuzziness were controlled by the number of 
points of the pharmacophore and the shapes of the bins. 
The fingerprint definition from Gobbi’s work [26], which 
is also implemented in RDKit, was used in this study. 
Table 3 demonstrates the target prediction performances 
of 3 types of pharmacophore definitions. With the same 2 
to 3 points in a pharmacophore, the comparison between 
differently shaped bins showed that rougher bin selection, 
indicating a fuzzier fingerprint, yielded higher sensitivity 
(43.6 vs. 42 %) but lower accuracy rate (64.2 vs. 66.7 %), 
precision (67 vs. 75.2 %), F0.5-Measure (0.61 vs. 0.65) and 
F0.25-Measure (0.657 vs. 0.719). However, an “extremely 
fuzzy” fingerprint with only 2 points in a pharmaco-
phore was not sufficiently informative to build an SEA 
model because it yielded a poor precision rate of 47.9 %, 
which indicates the false positive rate is more than 50 %. 
Pharmacophore-based fingerprints are a type of flexible 
molecular representation because the definition of the 
pharmacophore and the shape of the bin can vary, result-
ing in different levels of fuzziness. Fuzzy pharmacoph-
ores can also be used to identify compounds with similar 
pharmacological functions but structural differences [27, 
28]. The results in this section indicated that the fuzziness 
of the pharmacophore impacted the performance of the 
SEA greatly, and a well-designed pharmacophore scheme 
might improve the performance significantly. In the fol-
lowing sections, pharmacophore fingerprint-based SEA 
was built with point numbers of 2 and 3, and bin shapes 
(2,3), (3,4), (4,5), (5,6), (6,7), and (7,20).
SHED descriptors and Euclidean distance
We also tested the probability of SHED in building an 
SEA model. SHED is a pharmacophore-based descriptor 
schema including 4 pharmacophore definitions—hydro-
phobic, donor, acceptor and aromatic—as well as 10 
pairwise descriptors. As stated in the Methods section, 
Euclidean distance together with a normalized Eq.  (2), 
was used as a similarity criterion. Unlike with EVD, the 
Z-scores achieved from SHED followed a Gaussian dis-
tributions more closely. Although SHED has been suc-
cessfully used in some works [29, 30], the test results in 
this study showed that this type of schema is not proper 
for SEA models with poor precision (45.4  %) as well as 
F0.5-Measure (0.481) and F0.25-Measure (0.462), indicat-
ing that SHED, with 10 dimensional arrays, is not suffi-
ciently informative to build an accurate SEA model.
Table 2 Predictive results of SEA models with different activity thresholds (P value ≤ 0.05)
Threshold (μm) TS Accuracy Precision Sensitivity Specificity F0.5-Measure F0.25-Measure
0.1 0.69 0.568 0.958 0.072 0.997 0.278 0.557
1 0.69 0.592 0.94 0.129 0.993 0.417 0.687
10 0.62 0.676 0.826 0.382 0.93 0.67 0.772
Table 3 Predictive results of SEA models with different pharmacophore representations of compounds in fingerprints
Points of pharmacophore Bin shape Accuracy Precision Sensitivity Specificity F0.5-Measure F0.25-Measure
2 (0,2), (2,5), (5,8) 0.513 0.479 0.567 0.466 0.494 0.483
2, 3 (0,2), (2,5), (5,8) 0.642 0.678 0.436 0.821 0.61 0.657
2, 3 (2, 3), (3, 4), (4, 5), (5, 6), (6, 7), (7, 20) 0.667 0.752 0.42 0.88 0.65 0.719
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SEA with different types of fingerprints
To analyze the predictive power of different fingerprints 
in SEA models, in addition to Morgan and pharmaco-
phore models, another 3 SEA models were also built, 
including Atom pair, MACCS keys and Topological mod-
els. Table 4 shows the test results of 5 fingerprint-based 
SEA models. The prediction precision rates of the five 
fingerprint-based SEA models ranged from 75.2 to 83.7 % 
(at a P value ≤0.05) or from 85.6 to 92.1 % (at a P value 
≤ 0.01). More specifically, at significance level 0.05, The 
Topological model yielded the best precision rate (83.7 %) 
and F0.25-Measure (0.784) while The Atom pair model 
yielded the best F0.5-Measure (0.694). Therefore, the 
overall effectiveness of all of the models could be ranked 
in decreasing order as follows: Atom pair ≈ Topological 
> Morgan > MACCS > Pharmacophore. However, as can 
be observed from Table 4, in general, all the five models 
are comparable which consisted with previous work [4].
Multiple-voting SEA model
Kogej et al.’s [31] work demonstrated that much overlap 
was observed in selecting compounds using different 
fingerprints, and the combination of different finger-
prints yielded better performance [31]. Therefore, it was 
worthwhile to determine whether combining multiple 
SEA models could improve the predictive power. First, 
we calculated the overlaps of the number of true positive 
predictions of different fingerprint-based SEA models. 
Table  5 shows that most of the predictions of different 
models overlapped with each other. Taking Atom pair-
based model as an example, of the 15,944 true positive 
prediction, only 736 predictions overlapped with none 
of the predictions from other models. This finding was 
consistent with Kogej et al.’s work. Then, we constructed 
a multi-voting SEA model, as described in the following. 
To combine the 5 models, an election system was built 
by employing the P-value of each model as a vote. For 
example, if we took 3 votes into consideration (3-vote 
scheme), a ligand-target pair was significant only if there 
were more than three P-values less than the P-value cut-
off from the five SEA models. The test results of the 1 
to 5-vote SEA models are also included in Table  4. As 
expected, it can be found that precision increase with 
the vote cutoff of the model. Figure 2 presents the num-
ber of positive prediction, true positive prediction and 
the accuracy rates of different vote schemes at signifi-
cance level 0.05. The 1-vote scheme yielded 27,676 pre-
dictions, of which 19,644 were correct, and this number 
was more than half of the test set. However, the preci-
sion rate was relatively low (71 %). In contrast, the 5-vote 
scheme yielded a high precision of 90.6 % but a relatively 
small number of positive predictions at 13,122 (11,882 
were true positive). Moreover, with a significance level of 
0.01, the 5-vote scheme yielded a high accuracy of 94.1 % 
(see the Additional file 7: Fig. S4). Our results indicated 
that combining different fingerprints did improve the 
predictive performance of the SEA model. Because dif-
ferent fingerprints take charge of different aspects and 
features of a compound, the multi-voting SEA could be 
very robust (using a 1-vote scheme) for predicting tar-
get-ligand pairs and also accurate in its results (using the 
5-vote scheme).
Table 4 At significance level 0.05, the test result of different SEA models. The numbers after “Multi-voting” denote each 
voting scheme, e.g. Mult-voting (3) is a 3-vote scheme
Accuracy Precision Sensitivity Specificity F0.5-Measure F0.25-Measure
Atom pair 0.692 0.817 0.432 0.916 0.694 0.777
MACCS 0.682 0.802 0.417 0.911 0.677 0.76
Morgan 0.676 0.826 0.382 0.93 0.67 0.773
Topological 0.682 0.837 0.39 0.934 0.681 0.784
Pharmacophore 0.667 0.752 0.42 0.88 0.65 0.719
Multi-voting (1) 0.681 0.71 0.529 0.813 0.664 0.696
Multi-voting (2) 0.688 0.797 0.44 0.903 0.686 0.761
Multi-voting (3) 0.684 0.837 0.396 0.933 0.684 0.786
Multi-voting (4) 0.675 0.864 0.356 0.952 0.672 0.797
Multi-voting (5) 0.669 0.906 0.32 0.971 0.663 0.817
Table 5 The number of  overlaps of  true positive predic-
tions of each SEA model
Atom 
pair
MACCS Morgan Topological Pharmaco-
phore
Atom pair 16,044 13,853 13,335 13,805 13,600
MACCS 13,853 15,478 13,010 13,191 13,084
Morgan 13,335 13,010 14,176 13,282 12,902
Topological 13,805 13,191 13,282 14,467 12,814
Pharmacophore 13,600 13,084 12,902 12,814 15,594
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Kinase specific model
The Target class-specific model, by removing unrelated 
protein families or noise information, should improve 
the predictive performance. To confirm this assumption, 
a kinase-specific SEA model was constructed using a 
kinase training set based on Morgan fingerprint. When 
running on the kinase test set (2,192 positives, 818 
negatives), at significance level 0.05, the kinase-specific 
SEA model outperform Morgan-SEA-5 in precision 
100 vs. 94.8  %, but Morgan-SEA-5 model gave better 
F0.5-Measure (0.667 vs. 0.326) and F0.25-Measure (0.843 
vs. 0.621) result. Our results indicated that a target class-
specific SEA model could improve the prediction preci-
sion rate, all positive prediction were correct in this case. 
Therefore, a kinase-specific SEA model is useful and reli-
able (due to its high prediction accuracy) for capturing 
target relationships within the kinase families. As stated 
above, chemical similarity of the targets may not con-
sist with their sequence similarity. For enzyme activity 
classes, many targets were pharmacologically similar, 
with the higher ligands chemical similarity, but sequence 
dissimilar [5]. Research has also shown that linkage 
between two targets determined by chemical structural 
similarity rather than protein sequence might be more 
useful for drug discovery [4, 32]. Figure  3 shows a tar-
get relation network created using the kinase-specific 
SEA model. For clarity of the graphic illustration, only 
the most significant predictions are shown in the net-
work (P value ≤10−80). Despite the connection inside the 
subfamily of kinase, more than half (105 of 202) of the 
connections were across kinase subfamilies. For exam-
ple, serine/threonine-protein kinase PAK7 and AMP-
activated protein kinase alpha-2 subunit share 374 active 
compounds, and 16 of them are drugs; therefore there 
is a linkage between these two targets, although they 
are biologically unrelated (belonging to the STE pro-
tein kinase group and the CAMK protein kinase group, 
respectively).
Fig. 3 Target relation network for kinase using a kinase-specific SEA model. The nodes represent targets, and the linkages indicate significant (P 
value ≤10−80) relationships predicted by SEA. The nodes are colored according to 9 kinase subfamily types
(See figure on previous page.) 
Fig. 2 The upper plot illustrates the total number of positive (in red) and true positive predictions (in light blue) with different vote numbers, and the 
lower part is the corresponding precision
Page 9 of 10Wang et al. J Cheminform  (2016) 8:20 
Conclusion
In this work, we tested different aspects of SEA mod-
els, with the purpose of improving the accuracy rate 
of an SEA, indicating the activity threshold selection 
and the use of class-specific sets. The results showed 
that using stricter (activity cutoffs of 1 or 0.1  μm) and 
more specific training data could improve the predic-
tion accuracy rate of the SEA model but at the price 
of a smaller number of correct, positive predictions, 
indicating a higher false negative rate. To investigate 
the fuzzy nature of fingerprints, 3 pharmacophore fin-
gerprint-based SEA models were constructed and the 
comparison indicated that fuzzy fingerprints can yield 
larger numbers of predictions with overly rough repre-
sentation, which could lead to very low accuracy rates 
or even an impractical model. The comparison results 
of five different models showed that the Topological 
fingerprint-based SEA model outperformed the other 
models with the highest precision rate, and the Atom 
pair-based fingerprint yielded the greatest number of 
correct, positive predictions. The overall effectiveness of 
all of the models could be ranked in decreasing order as 
follows: Atom pair ≈ Topological> Morgan> MACCS> 
Pharmacophore. Although most of the predictions of 
each model were overlapped, the multi-voting model 
showed that combining multiple SEA models is a prom-
ising method for target prediction. With a tunable vote 
number, the multi-voting scheme can be flexible in its 
results, with either a high quality of prediction or a 
greater number of potential alternatives. It should be 
noted that the test results in this paper were optimistic 
because the test set used consisted of newly published 
data; thus, there were a great number of predictions that 
could not be proved for now and were not considered in 
the test results. Target-specific SEA could also improve 
the prediction accuracy.
An inherent assumption that molecules with simi-
lar structures tend to have similar responses to a target 
underlays SEA method. Thus, the challenge of improv-
ing SEA seems to be the same as “the traditional” ligand-
based drug discovery methods, such as Quantitative 
Structure-Activity Relationship or Virtual Screening. 
These methods suffered from the problem of the activ-
ity cliff, which is defined as pairs of structurally similar 
molecules with large differences in potency [33, 34]. Fin-
gerprints capable of distinguishing these compounds [28] 
could be used to improve SEA models.
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